CD38 and Miyoshi myopathy: These findings suggest that a combination of CD38-CAR or TRAILv-expressing NK cells with FL118-based treatment of MM cells could efficiently reverse BM-MSCs-dependent immunosuppression, and should therefore be further explored as a potentially novel approach to enhance CAR NK cell-based therapy for malignant diseases [36].